Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study

Current Medical Research and Opinion

Volumn 32, Issue 12, 2016, Pages 2047-2053

  Coleman, Craig I ^a   Antz, Matthias ^b   Bowrin, Kevin ^c   Evers, Thomas ^c   Simard, Edgar P ^d   Bonnemeier, Hendrik ^e   Cappato, Riccardo ^f  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b KLINIKUM OLDENBURG   (Germany)

^c BAYER PHARMA AG   (Germany)

^d Aetion   (United States)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Anticoagulants; Apixaban; Nonvalvular atrial fibrillation; Rivaroxaban; Stroke prevention; Warfarin

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTITHROMBOCYTIC AGENT; APIXABAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BILLING AND CLAIMS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONVALVULAR ATRIAL FIBRILLATION; PRESCRIPTION; RETROSPECTIVE STUDY; RISK REDUCTION; SAMPLE SIZE; UNITED STATES; STROKE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; HUMANS; MALE; PYRAZOLES; PYRIDONES; RETROSPECTIVE STUDIES; RIVAROXABAN; STROKE; UNITED STATES; WARFARIN;

EID: 84988373911     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1080/03007995.2016.1237937     Document Type: Article

References (23)

1. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRE guideline for the management of patients with atrial fibrillation:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2014;130:2071-204
2. Patel MR, Mahaffey KW, Garg J, et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91
3. Granger CB, Alexander JH, McMurray JJ, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92
4. Giugliano RP, Ruff CT, Braunwald E, et al.; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-104
5. Von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement:guidelines for reporting observational studies. J Clin Epidemiol 2008;61:344-9
6. Truven Health Analytics. MarketScan research databases. Available at:http://truvenhealth.com/Portals/0/assets/ACRS_11223_0912_MarketScanResearch_SS_Web.pdf [Last accessed 1 May 2016]
7. D’Agostino JrRB., Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-81
8. United States Food and Drug Administration. Drugs@FDA. Available at:https://www.accessdata.fda.gov/scripts/cder/drugsatfda/[Last accessed 1 May 2016]
9. Austin PC., Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput 2009;38:1228-34
10. Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage:the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011;58:395-401
11. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation:the Euro Heart Survey. Chest 2010;138:1093-100
12. Deyo RA, Cherkin DC, Ciol MA., Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
13. Go AS, Singer D, Cheetham C, et al. Mini-Sentinel Medical product assessment–a protocol for assessment of dabigatran, Version 3. Available at:http://www.mini-sentinel.org/work_products/Assessments/Mini-Sentinel_Protocol-for-Assessment-of-Dabigatran.pdf [Last accessed 15 March 2016]
14. R, Core Team. R:a language and environment for statistical computing. Vienna, Austria:R Foundation for Statistical Computing, 2013. Available at:http://www.R-project.org/[Last accessed 15 March 2016]
15. Noseworthy P, Yao X, Sangaralingham LR, et al. Direct comparison of dabigatran, rivaroxaban and apixaban for effectiveness and safety in nonvalvular atrial fibrillation. Oral presentation in Highlighted Original Research:Arrhythmias and Clinical EP and the Year in Review at the 65th Annual Meeting of the American College of Cardiology, Chicago, IL, USA, 2016
16. Yao X, Shah ND, Sangaralingham LR, et al. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulations in patients without severe renal impairment. Oral presentation at the 21st Annual International Meeting of the International Society of Pharmacoeconomics and Outcomes Research, Washington, DC, USA, May 2016
17. Fox KAA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011;32:2387-94
18. Alberts MJ, Peacock WF, Fields LE, et al. Association between once- and twice-daily direct oral anticoagulant adherence in nonvalvular atrial fibrillation patients and rates of ischemic stroke. Int J Cardiol 2016;215:11-13
19. McHorney CA, Crivera C, Laliberté F, et al. Adherence to non-vitamin-K-antagonist oral anticoagulant medications based on the Pharmacy Quality Alliance measure. Curr Med Res Opin 2015;31:2167-73
20. Coleman CI, Roberts MS, Sobieraj DM, et al. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin 2012;28:669-80
21. Coleman CI, Tangirala M, Evers T., Medication adherence to rivaroxaban and dabigatran for stroke prevention in patients with non-valvular atrial fibrillation in the United States. Int J Cardiol 2016;212:171-3
22. Shore S, Carey EP, Turakhia MP, et al. Adherence to dabigatran therapy and longitudinal patient outcomes:insights from the veterans health administration. Am Heart J 2014;167:810-17
23. Coleman CI, Antz M, Ehlken B, et al. REal-LIfe Evidence of stroke prevention in patients with atrial Fibrillation–the RELIEF study. Int J Cardiol 2016;203:882-4